
Shawgi Sukumaran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11243724/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 2012, 30, 2303-2317.	2.6	133
2	Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. , 2020, 8, e000281.		23
3	Is selfâ€management feasible and acceptable for addressing nutrition and physical activity needs of cancer survivors?. Health Expectations, 2015, 18, 3358-3373.	2.6	14
4	Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. Journal of Thoracic Disease, 2019, 11, 4241-4248.	1.4	13
5	Preâ€treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e64-e70.	1.1	11
6	Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review. World Journal of Oncology, 2014, 5, 232-236.	1.5	7
7	Predicting chemotherapyâ€induced menopause using baseline and postâ€chemotherapy antiâ€Müllerian hormone levels: Results of a pilot study. Cancer Reports, 2021, 4, e1342.	1.4	4
8	A Pilot Study of Self-Management-based Nutrition and Physical Activity Intervention in Cancer Survivors. Nutrition and Cancer, 2016, 68, 762-771.	2.0	3
9	Patterns of care in Jehovah's Witnesses patients with solid tumours and lymphoma. Cancer Reports, 2019, 2, e1148.	1.4	3
10	Realâ€world experience of nivolumab in the treatment of poor performance status patients with advanced nonâ€small cell lung cancer. Cancer Reports, 2021, , e1487.	1.4	2
11	Abstract C33: A twoâ€arm phase 1 clinical trial with NPIâ€0052, a novel proteasome inhibitor. , 2009, , .		2
12	Phase lb, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer Journal of Clinical Oncology, 2021, 39, 6075-6075.	1.6	1
13	What do patients with cancer think of the use of their tumor tissue for medical research?. Journal of Clinical Oncology, 2013, 31, 6541-6541.	1.6	1
14	Impact of age on treatment and survival in patients with small cell lung cancer Journal of Clinical Oncology, 2013, 31, e20577-e20577.	1.6	1
15	A prospective study of anti-mullerian hormone (AMH) as a predictor of chemotherapy-induced menopause Journal of Clinical Oncology, 2019, 37, e23076-e23076.	1.6	1
16	Variations in serum vitaminÂD status during cancer chemotherapy Journal of Clinical Oncology, 2012, 30, e19550-e19550.	1.6	1
17	An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with <i>TP53</i> wild-type relapsed/refractory small cell lung cancer Journal of Clinical Oncology, 2022, 40, TPS8600-TPS8600.	1.6	1
18	Outcomes of solid tumor malignancies in patients of Jehovah's Witness faith Journal of Clinical Oncology, 2017, 35, e18176-e18176.	1.6	0

#	Article	IF	CITATIONS
19	Feasibility of cancer treatment without blood transfusion in Jehovah's Witnesses Journal of Clinical Oncology, 2018, 36, e18554-e18554.	1.6	Ο
20	Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP) Journal of Clinical Oncology, 2020, 38, e16796-e16796.	1.6	0